Product
Supplier
Encyclopedia
Inquiry
Home > Active Pharmaceutical Ingredients > Other Chemical Drugs > Tirzepatide for Sale > High Purity Tirzepatide Lyophilized Powder CAS 2023788-19-2 Synthetic GLP-1/GIP Dual Agonist Peptide for Preclinical Research
High Purity Tirzepatide Lyophilized Powder CAS 2023788-19-2 Synthetic GLP-1/GIP Dual Agonist Peptide for Preclinical Research buy - large image1
High Purity Tirzepatide Lyophilized Powder CAS 2023788-19-2 Synthetic GLP-1/GIP Dual Agonist Peptide for Preclinical Research buy - image1
High Purity Tirzepatide Lyophilized Powder CAS 2023788-19-2 Synthetic GLP-1/GIP Dual Agonist Peptide for Preclinical Research buy - image2
High Purity Tirzepatide Lyophilized Powder CAS 2023788-19-2 Synthetic GLP-1/GIP Dual Agonist Peptide for Preclinical Research buy - image3
High Purity Tirzepatide Lyophilized Powder CAS 2023788-19-2 Synthetic GLP-1/GIP Dual Agonist Peptide for Preclinical Research buy - image4
High Purity Tirzepatide Lyophilized Powder CAS 2023788-19-2 Synthetic GLP-1/GIP Dual Agonist Peptide for Preclinical Research buy - image5
High Purity Tirzepatide Lyophilized Powder CAS 2023788-19-2 Synthetic GLP-1/GIP Dual Agonist Peptide for Preclinical Research buy - image6

High Purity Tirzepatide Lyophilized Powder CAS 2023788-19-2 Synthetic GLP-1/GIP Dual Agonist Peptide for Preclinical Research

TDS 2100 Inquiries

Unit Price: Get Latest Price
CAS No.:

2023788-19-2

Grade:

Pharmaceutical Grade

Content:

99%

Port:

ShenZhen

Brand:

XiWu

Packaging:

20mg*10Vials

Sample Available:

Yes

Price valid (until):

2026-10-09

Company Type:
Trader
Location:
China
Payment Terms:
TT against copy of documents,100% TT in advance
Average Lead Time:
1 days
Qualification:
Main Products:

GLP-1,Retatrutide,Selank,Tirzepatide

  • Product Details

  • Seller Information

  • Inquiry History

  • Description


       Product Detail  


    Items Specifications
    Product Name
    Tirzepatide Peptide Lyophilized Powder
    Purity ≥99%
    Packing Way Foam + Carton




    Whatsapp:+85244697127

    If you are interested, please feel free to contact me at any time.


    Product Introduction

    Tirzepatide is a synthetic 39‑amino‑acid modified peptide, dual GIP/GLP‑1 receptor agonist. Supplied as lyophilized powder for life‑science laboratory research. It is studied for incretin signaling, metabolic pathway and related pre‑clinical investigations.

    Chemical Information

    • Product Name: Tirzepatide
    • Synonyms: LY3298176
    • CAS No.: 2023788‑19‑2ECHEMI
    • Molecular Formula: C₂₂₅H₃₄₈N₄₈O₆₈
    • Molecular Weight: 4813.53 g/mol
    • Sequence: Tyr‑{Aib}‑Glu‑Gly‑Thr‑Phe‑Thr‑Ser‑Asp‑Tyr‑Ser‑Ile‑{Aib}‑Leu‑Asp‑Lys‑Ile‑Ala‑Gln‑{diacid‑C20‑gamma‑Glu‑(AEEA)2‑Lys}‑Ala‑Phe‑Val‑Gln‑Trp‑Leu‑Ile‑Ala‑Gly‑Gly‑Pro‑Ser‑Ser‑Gly‑Ala‑Pro‑Pro‑Pro‑Ser‑NH₂
    • Purity: ≥98%
    • Appearance: White to off‑white lyophilized powder
    • Solubility: Soluble in water and aqueous buffer solutions

    Mechanism of Action

    Tirzepatide is a dual‑receptor agonist that selectively binds and activates both GIP (glucose‑dependent insulinotropic polypeptide) receptor and GLP‑1 (glucagon‑like peptide‑1) receptor. Its C20 fatty‑diacid modification enables albumin binding to extend molecular half‑lifeFDA Access....

    In pre‑clinical research models:

    1. Pancreatic signaling: Stimulates glucose‑dependent insulin secretion from pancreatic β‑cells; suppresses glucagon release from α‑cells; modulates islet‑cell signaling pathwaysFDA Access

    2. Central nervous system: Acts on brain appetite‑regulating regions to modulate satiety and food‑intake related signaling pathways.

    3. Gastrointestinal effect: Delays gastric emptying in pre‑clinical assays, affecting post‑prandial nutrient handling.

    4. Peripheral metabolism: Modulates insulin‑sensitivity‑related signaling and lipid‑metabolism pathways in adipose and peripheral tissues in vitro and animal studies

    Storage Condition

    Lyophilized powder: Store at -20℃, sealed, dry, protected from light. Avoid repeated freeze‑thaw cycles. After reconstitution, keep at 2‑8℃ for short‑term use only.

    Shop High Purity Pinealon 175175-23-2 Lyophilized Powder For Laboratory Study-Detailed Image 1 Shop High Purity Pinealon 175175-23-2 Lyophilized Powder For Laboratory Study-Detailed Image 2 Shop High Purity Pinealon 175175-23-2 Lyophilized Powder For Laboratory Study-Detailed Image 3 Shop High Purity Pinealon 175175-23-2 Lyophilized Powder For Laboratory Study-Detailed Image 4 Shop High Purity Pinealon 175175-23-2 Lyophilized Powder For Laboratory Study-Detailed Image 5 Shop High Purity Pinealon 175175-23-2 Lyophilized Powder For Laboratory Study-Detailed Image 6 Shop High Purity Pinealon 175175-23-2 Lyophilized Powder For Laboratory Study-Detailed Image 7


    Shop Retatrutide Reta Triple Agonist Peptide for Metabolic Research-Detailed Image 6 Shop Retatrutide Reta Triple Agonist Peptide for Metabolic Research-Detailed Image 7



    Packaging & Logistics

    Standard packing: 5mg, 10mg, 50mg sealed vial.

    Outer package: Foam box + carton. Transportation: Normal cold chain transportation is optional. Goods will be well sealed to prevent moisture.

    Shop Retatrutide Reta Triple Agonist Peptide for Metabolic Research-Detailed Image 8 Shop Retatrutide Reta Triple Agonist Peptide for Metabolic Research-Detailed Image 9


    Shop Retatrutide Reta Triple Agonist Peptide for Metabolic Research-Detailed Image 10 Shop Retatrutide Reta Triple Agonist Peptide for Metabolic Research-Detailed Image 11


    Company Profile


    We are a high-tech enterprise oriented towards research and development, specializing in the fields of pharmaceutical raw materials, intermediates, peptide components, cosmetic raw materials, and nutritional supplement raw materials. We offer standardized large-scale production services and conduct global wholesale business. Our multiple peptide raw materials possess core physiological effects such as weight loss, muscle building, blood sugar reduction, and anti-aging, are widely applicable to the research and production demands in the pharmaceutical, beauty, and health care sectors.

    We adopt strict batch production standards and have sufficient production capacity and stable supply capabilities. All products have been professionally tested by third-party institutions and come with complete test reports and qualification certificates, ensuring stable batch quality and complete traceability. For large-scale orders, we offer competitive wholesale prices. We uphold the core values of integrity, pragmatism, innovation and development, and continuously enhance our technical strength and product quality.


    We offer comprehensive high-quality fine raw materials for the pharmaceutical, cosmetic and nutritional product industries. At the same time, we not only support standard batch purchases but also can meet the needs of pilot projects and large-scale industrial production.

    ECHEMI Editorial Reference

    Tirzepatide (LY3298176) was developed as a dual agonist to both GLP-1 and gastric inhibitory polypeptide (GIP) receptors (Frias et al., 2018). Similar to GLP-1, GIP is an incretin hormone that functions to induce insulin secretion.

    Certificates

    Basic Info
    Product Name:

    Tirzepatide

    Other Name:

    LY3298176;

    CAS No.:

    2023788-19-2

    Molecular Formula:

    C225H348N48O68

    Molecular Weight:

    4813

    EC Number:

    200-001-8

    Categories:

    Other Chemical Drugs

    Characteristics
    Appearance:

    White to off-white

    Research
    Class:

    Dual agonist — GIPR, GLP-1R

    Status:

    FDA-approved (Mounjaro / Zepbound)

    Mechanism:

    Dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. A 39-amino-acid modified peptide with a C20 fatty diacid moiety that enables albumin binding for extended half-life (~5 days). Selectively activates both GIPR and GLP-1R signaling pathways.

    EC50 (Human GLP1R):

    0.934 nM

    EC50 (Human GIPR):

    0.0224 nM

    Source:

    Frias JP, et al. N Engl J Med. 2021;385(6):503-515.DOI

    FDA:

    Mounjaro, Zepbound (approved 2022-05-13)

    References
    ChEMBL:

    CHEMBL4297839

    DrugBank:

    DB15171

    KEGG DRUG:

    D11360

    PubChem:

    PubChem

    Disclaimer:

    Tirzepatide is approved as a prescription medicine (Mounjaro, Zepbound) in certain jurisdictions. This listing is for industrial and laboratory research use only. Research-chemical listings on B2B marketplaces are not interchangeable with approved medicines. Confirm CAS, specification, and regulatory pathway with the seller. It is not medical advice, a clinical recommendation, or an approved therapy description.

  • Seller Information
    Business Type:

    Trader

    Main Products:

    GLP-1,Retatrutide,Selank,Tirzepatide

    Location:

    Room 307, No. 3, Building 7, Area 4, Pingchou, Jiangdong Street, Yiwu City, Jinhua City, Zhejiang Province

    Payment Terms:

    TT against copy of documents,100% TT in advance

    Average lead Time:

    1 days

    Total Annual Revenue:

    Less than $1 million

    Total Employees:

    11-50

    Year of Establishment:

    2026

  • Inquiry History
    2100 Inquiries
    Country Product Purchase Quantity Date Posted
    Slovakia

    Tirzepatide

    1 G Oct 26, 2026
    France

    Tirzepatide

    1 KG Oct 25, 2026
    United States

    Tirzepatide

    2.5 MG Oct 25, 2026
    United Kingdom

    Tirzepatide

    5 MT Oct 25, 2026
    United Kingdom

    Tirzepatide

    6 MT Oct 24, 2026
    Peru

    tirzepatide

    10 MG Oct 21, 2026
    Puerto Rico

    tirzepatide

    40 MG Oct 21, 2026
    United States

    Tirzepatide

    10 MT Oct 21, 2026
    South Africa

    Tirzepatide

    1 MT Oct 20, 2026
    United States

    Tirzepatide

    5 KG Oct 20, 2026
    United States

    tirzepatide

    30 MG Oct 20, 2026
    United States

    Tirzepatide

    50 MG Oct 20, 2026
    Spain

    tirzepatide

    20 MG Oct 19, 2026
    United States

    tirzepatide

    30 MG Oct 19, 2026
    Philippines

    tirzepatide

    40 MG Oct 19, 2026
    United States

    tirzepatide

    50 MG Oct 19, 2026
    United States

    tirzepatide

    50 MG Oct 19, 2026
    United States

    Tirzepatide

    20 MG Oct 19, 2026
    United States

    Tirzepatide

    300 MG Oct 19, 2026
    China

    Tirzepatide

    21 MT Oct 17, 2026
    Post an enquiry for this product
pic ×

Scan the QR Code to Share

All products displayed on this website are only for non-medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.

According to relevant laws and regulations and the regulations of this website, units or individuals who purchase hazardous materials should obtain valid qualifications and qualification conditions.

The information shown above is provided by the enterprise itself, and the authenticity, accuracy and legitimacy of the content are the responsibility of the publishing company. ECHEMI does not bear any guarantee responsibility for this. Please be aware that risks in internet transactions objectively exist.

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.